Stada suffers €97m collateral damage as Serbian state fails to pay its own wholesaler

The likelihood that Serbian pharmaceutical wholesalers will default on their debts has led German wholesaler Stada, which has a leading position in the market, to book a one-off pre-tax special impairment of €97 million for the third quarter. In particular, Stada is owed money by the country's largest wholesaler, Velefarm, which is majority owned by the state and just under 20% owned by Stada itself.

The likelihood that Serbian pharmaceutical wholesalers will default on their debts has led German wholesaler Stada, which has a leading position in the market, to book a one-off pre-tax special impairment of €97 million for the third quarter. In particular, Stada is owed money by the country's largest wholesaler, Velefarm, which is majority owned by the state and just under 20% owned by Stada itself.

Stada wrote down €29.5 million in the third quarter last year also because of outstanding debts from Velefarm and other local wholesalers

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Finance Watch: Funding Alternatives Become The Norm In Tough Public Markets

 
• By 

Public Company Edition: With fewer follow-on offerings, drug developers are pursuing other options. Axsome accessed up to $570m in debt, Evolus obtained $250m in a new credit facility and Abeona raised $155m from a PRV sale, but Apimeds was able to execute a small $13.5m IPO.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By 

As CEO Anderson backs high prices for innovative drugs in Europe

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By 

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.

More from Scrip

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By 

As CEO Anderson backs high prices for innovative drugs in Europe

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By 

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.